• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Taris Biomedical

Taris Bio, Bristol-Myers Squibb launch bladder cancer trial

July 12, 2019 By Nancy Crotti

Taris Biomedical has announced the dosing of the first patient in a study of its TAR-200 system plus a programmed immune checkpoint inhibitor for the treatment of muscle-invasive bladder cancer (MIBC). The TAR-200 system continuously delivers the chemotherapy drug gemcitabine in the bladder for multiple weeks. The combination with Bristol-Myers Squibb’s Opdivo (nivolumab) will be […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Oncology, Uncategorized Tagged With: Bristol-Myers Squibb Co., Taris Biomedical

Taris Biomedical touts results of bladder cancer treatment study

June 27, 2019 By Nancy Crotti

Taris Biomedical today announced positive results from the second arm of a study of its TAR-200 system for the treatment of patients with muscle-invasive bladder cancer (MIBC). The most recent study arm involved 10 patients treated with TAR-200 and yielded positive safety, tolerability and preliminary efficacy data, according to Lexington, Mass.-based Taris. Combined data from […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Uncategorized Tagged With: Taris Biomedical, University of Southern Callifornia

Taris Biomedical lands $25m Series B following Bristol-Myers deal

December 21, 2017 By Sarah Faulkner

Taris Biomedical

One day after announcing a research collab with Bristol-Myers Squibb (NYSE:BMY), Taris Biomedical revealed that it has raised $25 million in a Series B round. Bristol-Myers also contributed to the round, which was led by Yonghua Capital. “We have made substantial progress on our lead programs in bladder cancer and overactive bladder,” president & CEO Purnanand Sarma said […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Taris Biomedical

Bristol-Myers Squibb taps Taris’ drug-release tech for bladder cancer trial

December 20, 2017 By Sarah Faulkner

Taris Biomedical

Bristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo, in a Phase Ib muscle invasive bladder cancer trial. As part of the collaboration, Bristol-Myers has also made an equity investment in Lexington, Mass.-based Taris. Taris’ GemRIS system is designed […]

Filed Under: Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Taris Biomedical

Taris Biomedical closes enrollment in phase Ib trial for drug-device combo

January 6, 2017 By Sarah Faulkner

Taris Biomedical

Taris Biomedical said today that it closed initial enrollment in its phase Ib clinical trial following positive results. The study is evaluating the safety and efficacy of its drug-device combination product that releases gemcitabine continuously into the bladder for 7 days in patients with muscle invasive bladder cancer. Although the study was slated to enroll […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology Tagged With: Taris Biomedical

Taris launches another Phase I trial for bladder cancer drug-device combo

August 10, 2016 By Fink Densford

Taris Biomedical said today it is launching a new phase I trial of its TAR-200 gemcitabine releasing intravesical system designed to deliver drugs directly to the bladder for patients with non-muscle-invasive bladder cancer. The phase 1b open-label study is slated to enroll 30 patients to explore whether continuous, local exposure to gemcitabine using TAR-200 is […]

Filed Under: Clinical Trials, Drug-Device Combinations, Oncology Tagged With: Taris Biomedical

Taris reboots with $32m round for bladder tech

October 27, 2015 By Brad Perriello

A year after dealing its Liris bladder treatment to Allergan in a deal worth up to $588 million, Taris Biomedical raised another $32 million to put toward the implant, which is designed to deliver drugs directly to the bladder. Allergan paid $67.5 million in cash in August 2014 for Liris, a drug-device combination designed to deliver lidocaine to treat […]

Filed Under: Drug-Device Combinations Tagged With: Taris Biomedical, Venture Capital/Private Equity

Taris taps new CEO

July 19, 2010 By drugdelivery

Taris logo

Taris Biomedical hired Sarma Duddu to be its new president and CEO.

The Lexington, Mass.-based durg/device developer said Duddu brings 15 years of pharmaceutical industry experience to the corner office, where he’ll start immediately.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Taris Biomedical

Taris Biomedical launches with $15 million financing round

June 25, 2009 By drugdelivery

Taris Biomedical hit the ground running, raising $15 million from venture fund backers for its launch.

The Lexington-based drug-device developer, which is aiming to leverage lidocaine delivery technology developed at MIT to treat bladder conditions, said (PDF) Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners led the investment round.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Taris Biomedical

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS